Navigation Links
Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting
Date:5/29/2009

NEW HAVEN, Conn., May 29 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

The poster (Abstract #7050) entitled "Comorbidity Description Using the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Elderly de novo Poor Risk AML Patients Treated with Laromustine" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M4 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009. A copy of the poster will be available on Vion Pharmaceuticals' website, www.vionpharm.com, on May 30, 2009 at 8:00 a.m. Eastern Time.

In addition, the Company announced that additional data on Onrigin would be presented in a poster from an investigator-sponsored trial of Onrigin in combination with cytarabine in elderly patients with previously untreated AML. The trial is sponsored by the Weill-Cornell Medical College. The poster (Abstract #7054) entitled "Phase I Trial of Laromustine in Combination with Infusional Ara-C in Elderly Patients Over Age 60 with Newly Diagnosed AML or High-Grade MDS" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M10 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The Company has an NDA under review with the FDA fo
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
2. American Academy of Dermatology Recognizes Merz Pharmaceuticals
3. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
4. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
5. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
6. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
7. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
8. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
9. Agios Pharmaceuticals founders author Science review on cancer metabolism
10. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
11. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 Information ... Pros company to introduce better prices to consumers in ... plans can be found when using the open system ... national lookup system available to use this year can ... insurance based on general location and not from medical ...
(Date:8/30/2014)... Daily Gossip magazine reveals in its "Panic ... attacks under control with a simple and efficient method. ... this new method as an anxiety recovery program which ... general anxiety related disorders. , What makes this ... it can be accessed by users from the comfort ...
(Date:8/30/2014)... Ticket Down is a reliable ... in NYC. This popular ticket exchange has ... day session, evening session, courtside seats, grandstand seats, general ... Grand Slam Tournament. , The 2014 U.S. Open Tennis ... Tennis Championship: Men's/Women's 3rd Round - Session 11 Tickets ...
(Date:8/30/2014)... 2014 Seniors Guide, the comprehensive guide to ... on Alzheimer’s Disease, Dementia, and Memory Loss . , ... of being diagnosed with the Alzheimer’s, inspired Seniors Guide writers ... Me”. The movie, out on October 14, 2014, shows ... diagnosis of the disease – which inspires a final tour ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Nearly 100 people have been bitten and injured by a ... vaccines in the government hospitals to treat the patients. ... attacked and injured villagers - including women and children - ... the district, about 200 km from here. ...
... tweak the fertility of rats, believe many in Mizoram. Now ... the Mizo menu and even the bedroom! ... of the tall grass every 50 years are considered a ... The seeds trigger a phenomenal rodent population explosion as the ...
... international team that has for the first time reversed ... raising hopes of drug therapy for this disorder that ... the National Centre for Biological Sciences (NCBS) and National ... have contributed to the breakthrough, reported this week's Proceedings ...
... ahead with its campaign against pollution and global warming, whatever ... ,It has now come out with a report warning ... our times" and could set off mass migrations of people ... in arid regions to revise rules on land use to ...
... Standards survey study found that smaller amount of teenagers are drinking on ... harder for youngsters to get hold of alcohol. Those who never ... in the latest research. Those who drink on a regular basis - ... On the other hand a third of those who do drink do ...
... Thursday to ban all female circumcision, the widely-practised removal of ... of a 12-year-old girl. ,Officially the practice, which ... back to the time of the pharaohs, was banned in ... ,Health Minister Hatem al-Gabali has decided to ban ...
Cached Medicine News:Health News:Bamboo Seed: Viagra and Food for Mizos 2Health News:Research Shows Way for Drug Therapy for Autism 2Health News:Desertification, a Major Threat, Says UN 2Health News:New Study That Small Amount of Teenagers Drinks on a Regular Basis 2Health News:Egypt Outlaws All Female Circumcision 2
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Jan. 6, 2011 Viveve, Inc. , a ... has received the European CE (Conformite Europeenne) mark for ... treatment of laxity of the vaginal introitus (opening), after ...   http://photos.prnewswire.com/prnh/20110106/SF25673LOGO ) "The CE mark is ...
... VRUS ), announced today positive data from interim analyses ... 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the ... Pipeline Update and 2011 Highlights PSI-7977 ... pegylated interferon and ribavirin (Peg-IFN/RBV) in a Phase 2b study. This ...
Cached Medicine Technology:Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity 2Pharmasset Reports Positive Results from its HCV Clinical Programs 2Pharmasset Reports Positive Results from its HCV Clinical Programs 3Pharmasset Reports Positive Results from its HCV Clinical Programs 4Pharmasset Reports Positive Results from its HCV Clinical Programs 5Pharmasset Reports Positive Results from its HCV Clinical Programs 6
... The BioPlex 2200 system is ... platform that can deliver up to ... will initially include a panel of ... in development are in the areas ...
... ASR contains primers and a FAM-labeled probe targeting ... as well as primers and an Alexa 532-labeled ... of HSV Type 2. This ASR requires an ... Alexa reporter dyes like the Cepheid SmartCycler System. ...
... and a FAM-labeled probe that is designed to ... Type 1 and Type 2 polymerase gene. This ... FAM reporter dye like the Cepheid SmartCycler System. ... is comprised of a series of easy-to-use primer ...
... The Stratus CS Analyzer, designed for Acute Care ... your laboratory and near patient setting. It's a ... or D-Dimer results from a whole blood sample ... 3 step process load sample and rotor, ...
Medicine Products: